5 April 2017 - PHARMAC is pleased to announce the approval of a listing agreement for the supply of orthopaedic implants and associated products with LMT Surgical.

This was the subject of a consultation letter dated 9 March 2017.

In summary, the effect of the decision is that:

• A range of orthopaedic implants and associated products will be listed in Section H, Part III, (‘Optional Pharmaceuticals’) of the Pharmaceutical Schedule from 1 May 2017.
  
• DHB hospitals can purchase these items directly from LMT Surgical
  
• It will deliver national savings of approximately $20,000 per annum
  

Read PHARMAC notification